Mark McDonnell

Dr. McDonnell spent the majority of his career at Johnson and Johnson Pharmaceuticals, where he focused on CNS and Pain Therapeutics, including an endocannabinoid program. Dr. McDonnell has designed and synthesized thousands of novel, pharmacologically active compounds, and has led several projects from hit identification through lead optimization. He has demonstrated a rare combination of creative thought and high productivity in the laboratory. Working now at Fox Chase Chemical Diversity Center, Inc. and Vironika, LLC, he continues investigations in the CNS area, including projects on Alzheimer’s Disease and ALS, and viral-mediated cancers such as nasopharyngeal carcinoma.